Cabaletta Bio, Inc.
CABADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
28dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How CABA's past catalysts played out
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Idiopathic Inflammatory Myopathy
CABA-201
Generalized Myasthenia Gravis (gMG)
DSG3-CAART
Pemphigus Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CABA-201 following preconditioning with fludarabine and cyclophosphamide | Phase 3 | Idiopathic Inflammatory Myopathy | - | - |
CABA-201 | Phase 2 | Generalized Myasthenia Gravis (gMG) | - | - |
DSG3-CAART | Phase 2 | Pemphigus Vulgaris | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cabaletta Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cabaletta Bio, Inc.'s (CABA) pipeline across Phase 3, Phase 2. Its lead program is CABA-201 following preconditioning with fludarabine and cyclophosphamide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cabaletta Bio, Inc.'s next FDA catalyst?→
Cabaletta Bio, Inc.'s (CABA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CABA biotech catalysts?→
Add CABA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cabaletta Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.